Xingping Qin
YOU?
Author Swipe
View article: De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer
De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer Open
Oncogenic KRAS induces metabolic rewiring in pancreatic ductal adenocarcinoma (PDAC) characterized, in part, by dependency on de novo pyrimidine biosynthesis. Pharmacologic inhibition of dihydroorotate dehydrogenase (DHODH), an enzyme in t…
View article: Paclitaxel-induced mitotic arrest results in a convergence of apoptotic dependencies that can be safely exploited by BCL-X<sub>L</sub>degradation to overcome cancer chemoresistance
Paclitaxel-induced mitotic arrest results in a convergence of apoptotic dependencies that can be safely exploited by BCL-X<sub>L</sub>degradation to overcome cancer chemoresistance Open
Paclitaxel and other microtubule-targeting agents are cornerstone therapies for diverse cancers, including lung, breast, cervical, pancreatic, and ovarian malignancies. Paclitaxel induces tumor cell apoptosis during mitosis by disrupting m…
View article: LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers
LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers Open
The efficacy of molecularly targeted therapies may be limited by co-occurring mutations within a tumor. Conversely, these alterations may confer collateral vulnerabilities that can be therapeutically leveraged. KRAS -mutant lung cancers ar…
View article: Research on Employment Sentiment Analysis of College Graduates Based on Global and Local Key Fusion Features
Research on Employment Sentiment Analysis of College Graduates Based on Global and Local Key Fusion Features Open
The increasingly fierce competition in the job market has brought unprecedented pressure and challenges to college students who are struggling to find a job. In order to address the manual analysis insufficiency of the mental state of coll…
View article: Supplementary Figure S5 from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX
Supplementary Figure S5 from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX Open
Supplementary Figure S5
View article: Data from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX
Data from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX Open
Although external beam radiation therapy (xRT) is commonly used to treat central nervous system (CNS) tumors in patients of all ages, young children treated with xRT frequently experience life-altering and dose-limiting neurocognitive impa…
View article: Supplementary Figure S3 from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX
Supplementary Figure S3 from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX Open
Supplementary Figure S3
View article: Supplementary Figure S6 from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX
Supplementary Figure S6 from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX Open
Supplementary Figure S6
View article: Supplementary Figure S5 from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX
Supplementary Figure S5 from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX Open
Supplementary Figure S5
View article: Supplementary Figure S2 from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX
Supplementary Figure S2 from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX Open
Supplementary Figure S2
View article: Supplementary Figure S6 from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX
Supplementary Figure S6 from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX Open
Supplementary Figure S6
View article: Supplementary Figure S1 from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX
Supplementary Figure S1 from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX Open
Supplementary Figure S1
View article: Supplementary Figure S3 from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX
Supplementary Figure S3 from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX Open
Supplementary Figure S3
View article: Supplementary Figure S2 from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX
Supplementary Figure S2 from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX Open
Supplementary Figure S2
View article: Supplementary Figure S4 from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX
Supplementary Figure S4 from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX Open
Supplementary Figure S4
View article: Supplementary Figure S1 from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX
Supplementary Figure S1 from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX Open
Supplementary Figure S1
View article: Supplementary Figure S4 from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX
Supplementary Figure S4 from Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX Open
Supplementary Figure S4
View article: De novo pyrimidine biosynthesis inhibition synergizes with BCL-X<sub>L</sub>targeting in pancreatic cancer
De novo pyrimidine biosynthesis inhibition synergizes with BCL-X<sub>L</sub>targeting in pancreatic cancer Open
Oncogenic KRAS, the genetic driver of 90% of pancreatic adenocarcinoma (PDAC), induces a metabolic rewiring characterized, in part, by dependency on de novo pyrimidine biosynthesis. Pharmacologic inhibition of dihydroorotate dehydrogenase …
View article: Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma
Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma Open
View article: In situ architecture of Opa1-dependent mitochondrial cristae remodeling
In situ architecture of Opa1-dependent mitochondrial cristae remodeling Open
View article: Supplementary Figure S4 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX
Supplementary Figure S4 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX Open
Supplementary Figure S4
View article: Supplementary Figure S2 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX
Supplementary Figure S2 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX Open
Supplementary Figure S2
View article: Supplementary Figure S6 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX
Supplementary Figure S6 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX Open
Supplementary Figure S6
View article: Supplementary Figure S4 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX
Supplementary Figure S4 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX Open
Supplementary Figure S4
View article: Supplementary Figure S5 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX
Supplementary Figure S5 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX Open
Supplementary Figure S5
View article: Supplementary Figure S1 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX
Supplementary Figure S1 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX Open
Supplementary Figure S1
View article: Data from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX
Data from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX Open
Although external beam radiotherapy (xRT) is commonly used to treat central nervous system (CNS) tumors in patients of all ages, young children treated with xRT frequently experience life-altering and dose-limiting neurocognitive impairmen…
View article: Supplementary Figure S3 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX
Supplementary Figure S3 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX Open
Supplementary Figure S3
View article: Data from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX
Data from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX Open
Although external beam radiotherapy (xRT) is commonly used to treat central nervous system (CNS) tumors in patients of all ages, young children treated with xRT frequently experience life-altering and dose-limiting neurocognitive impairmen…
View article: Supplementary Figure S6 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX
Supplementary Figure S6 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX Open
Supplementary Figure S6